This post is part of HED’s Drugs in the Pipeline series, covering drugs that have not yet received FDA approval but have reached meaningful regulatory or clinical milestones. These posts are distinct from approval coverage: the drug discussed here is investigational, not approved, and the evidence described is preliminary. They are published to help readers track what is coming and understand what the data already suggests.

The essentials: On August 3, 2026, Eli Lilly announced that the FDA granted Breakthrough Therapy Designation to olomorasib (LY3537982) as a monotherapy for adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. This is olomorasib’s second Breakthrough Therapy Designation: the first was granted in September 2025 for the combination of olomorasib plus pembrolizumab in first-line KRAS G12C-mutant non-small cell lung cancer with PD-L1 expression at or above 50%. What Breakthrough Therapy Designation means: it does not constitute FDA approval and does not guarantee approval will follow. It indicates that preliminary clinical evidence suggests the potential for substantial improvement over available therapy on a clinically significant endpoint, and it triggers more intensive FDA guidance throughout drug development and may shorten the path to approval. What olomorasib is: an oral, potent, highly selective next-generation inhibitor of the KRAS G12C protein, administered orally once daily. It is part of a class of direct KRAS G12C inhibitors that includes the approved agents sotorasib (Lumakras, AMG 510, Amgen) and adagrasib (Krazati, MRTX849, Mirati/BMS). Olomorasib is designed to have enhanced potency and selectivity over these first-generation agents. The clinical basis for the designation: preliminary findings from the open-label, multicenter Phase 1/2 LOXO-RAS-20001 study (NCT04956640), which is evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumors, including a pancreatic cancer cohort. Specific Phase 1/2 efficacy data numbers have not been publicly disclosed in detail. The designation itself reflects FDA agreement that the preliminary clinical signal in the pancreatic cancer cohort is clinically meaningful. Why this matters in the context of HED’s recent coverage: on July 22, 2026, the FDA accepted Revolution Medicines’ NDA for daraxonrasib (RMC-6236, a pan-RAS multi-selective inhibitor) for previously treated metastatic pancreatic cancer based on the landmark RASolute 302 Phase 3 data. Olomorasib, which specifically targets only KRAS G12C (approximately 1 to 2% of pancreatic cancers), and daraxonrasib, which targets all RAS mutations regardless of specific variant, represent two distinct molecular approaches to the same oncogenic pathway in one of the hardest-to-treat cancers in medicine. Currently no FDA-approved therapies specifically target KRAS G12C-mutant pancreatic cancer.

In June 2026, HED published a post on daraxonrasib and the RASolute 302 trial, which generated a standing ovation at the ASCO plenary and produced the most dramatic overall survival improvement seen in second-line metastatic pancreatic cancer to date. The daraxonrasib story centered on what happens when you target active RAS proteins comprehensively, across all mutation types, rather than focusing on a single mutation. The olomorasib story is the parallel track: what happens when you target the most common specific KRAS mutation as precisely and potently as current chemistry allows.

These are not competing approaches. They are complementary ones, addressing different portions of the KRAS-driven pancreatic cancer population and potentially, in the future, different positions in the treatment sequence. Understanding why both exist and why the FDA is prioritizing both with Breakthrough Therapy Designation requires understanding the KRAS mutation landscape in pancreatic cancer and the specific pharmacological problem that KRAS G12C inhibitors were built to solve.

---

The KRAS Mutation Landscape in Pancreatic Cancer: Where G12C Fits

As covered in the daraxonrasib post, more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases harbor a RAS mutation. The distribution across specific mutations matters for understanding which drug applies to which patient:

KRAS mutation	Approximate frequency in PDAC	Targeted by
KRAS G12D	Approximately 42%	Daraxonrasib (pan-RAS); MRTX1133 (investigational G12D specific)
KRAS G12V	Approximately 32%	Daraxonrasib (pan-RAS)
KRAS G12R	Approximately 14%	Daraxonrasib (pan-RAS)
KRAS G12C	Approximately 1 to 2%	Olomorasib; sotorasib; adagrasib; daraxonrasib (pan-RAS)
Other variants	Remaining	Daraxonrasib (pan-RAS)

The G12C mutation, which substitutes glycine for cysteine at codon 12 of the KRAS protein, is present in only 1 to 2% of pancreatic cancers. In absolute terms, with approximately 66,000 pancreatic cancer diagnoses annually in the United States, that translates to roughly 660 to 1,320 new G12C-mutant PDAC cases per year. It is a small population in an already rare-disease context.

The G12C mutation is more common in NSCLC (approximately 13% of cases), which is why the clinical development of KRAS G12C inhibitors began primarily in lung cancer, where sotorasib and adagrasib were first approved. Their activity in pancreatic cancer with the same mutation has been far more modest: single-agent response rates of 10 to 21% in pancreatic cancer versus 36 to 45% in NSCLC, reflecting the distinct biology of the pancreatic tumor microenvironment.

The reason olomorasib is generating enough preliminary signal to earn Breakthrough Therapy Designation in pancreatic cancer, despite this historically poor performance of KRAS G12C inhibitors in PDAC, is the core clinical story of the pipeline series.

---

What Makes Olomorasib a “Next-Generation” KRAS G12C Inhibitor

Olomorasib (LY3537982) is developed by Eli Lilly (via its Loxo Oncology acquisition) as an oral, highly selective covalent inhibitor of KRAS G12C. Like sotorasib and adagrasib, it works by exploiting the unique cysteine at position 12 that the G12C mutation creates. The drug covalently binds to this cysteine in the inactive (GDP-bound) form of the KRAS G12C protein, locking the protein in an inactive conformation that prevents downstream signaling.

The “next-generation” designation reflects several pharmacological improvements Lilly has engineered compared to the first approved KRAS G12C inhibitors:

Higher potency: Olomorasib demonstrates substantially higher biochemical potency against KRAS G12C than sotorasib or adagrasib in preclinical assays. Higher potency means more complete target occupancy at clinically achievable doses, which translates into more effective suppression of KRAS G12C-driven signaling.

Higher selectivity: Olomorasib has a cleaner selectivity profile against closely related kinases and off-target proteins, which is expected to reduce off-target adverse effects and potentially allow higher effective doses.

Improved pharmacokinetics: Oral bioavailability and half-life characteristics support once-daily dosing with consistent drug exposure throughout the dosing interval, maintaining effective target coverage between doses.

Activity against resistance mutations: First-generation KRAS G12C inhibitors develop resistance in part through acquired secondary mutations in KRAS (including Y96D, H95) and through alternative pathway activation. Olomorasib’s binding mode and potency may provide some advantage against known resistance mechanisms, though this remains an area of active preclinical and clinical investigation.

In NSCLC, where KRAS G12C inhibitors are most established, olomorasib has demonstrated response rates in the LOXO-RAS-20001 trial that exceed what was seen with first-generation agents, supporting the next-generation positioning. The pancreatic cancer Breakthrough Therapy Designation suggests a similar step-up in activity in PDAC, though the specific data supporting the designation have not yet been fully disclosed publicly.

---

The LOXO-RAS-20001 Study: What Is Known

LOXO-RAS-20001 (NCT04956640) is an open-label, multicenter Phase 1/2 basket trial evaluating olomorasib across KRAS G12C-mutant advanced solid tumors. The trial includes:

Phase 1a: Dose escalation evaluating olomorasib monotherapy safety and pharmacokinetics across KRAS G12C-mutant solid tumors to establish the recommended Phase 2 dose.

Phase 1b: Dose expansion and optimization evaluating olomorasib as monotherapy and in combination regimens (with pembrolizumab, with chemotherapy, and with other standard-of-care agents) across defined tumor-type cohorts.

The pancreatic cancer cohort within the dose expansion phase enrolled patients with advanced PDAC harboring KRAS G12C mutation who had received at least one prior systemic therapy, consistent with the Breakthrough Therapy Designation eligibility criteria.

Lilly has indicated that the Breakthrough Therapy Designation was based on encouraging preliminary findings from this study in the pancreatic cancer cohort. Specific ORR, DOR, and PFS numbers for the pancreatic cancer cohort have not been fully publicly disclosed as of the time of writing. Updated data from LOXO-RAS-20001, including pancreatic cancer cohort results, are expected at major oncology conferences in late 2026 and 2027 as the program matures and a pivotal trial design is finalized.

In the NSCLC cohorts of LOXO-RAS-20001, published data and ASCO presentations have shown response rates in the 35 to 45% range for olomorasib monotherapy, substantially exceeding the rates achieved with sotorasib and adagrasib in similar NSCLC populations. If even a fraction of that improvement over first-generation agents translates to the pancreatic cancer cohort, it would represent a meaningful advance over the 10 to 21% response rates seen with first-generation KRAS G12C inhibitors in PDAC.

---

The Competitive Landscape: How Olomorasib Relates to Daraxonrasib

Given HED’s recent coverage of daraxonrasib and RASolute 302, it is worth being explicit about how these two drugs relate and why both are being actively developed in pancreatic cancer.

The fundamental difference is mechanistic breadth: daraxonrasib targets all active RAS proteins regardless of which specific mutation is driving activity, while olomorasib targets only KRAS G12C. For the 1 to 2% of pancreatic cancer patients with KRAS G12C mutations, both are potentially applicable.

Whether a mutation-specific inhibitor or a pan-RAS inhibitor is superior for KRAS G12C-mutant PDAC is a question clinical data will need to answer. The theoretical argument for the mutation-specific approach is that a more targeted inhibitor can achieve deeper and more sustained KRAS G12C suppression without the off-target effects of broader RAS inhibition. The theoretical argument for the pan-RAS approach is that it closes more escape pathways: even in G12C-mutant tumors, pathway feedback and cross-activation may maintain some wild-type RAS activity, and blocking only G12C leaves those escape routes open.

In practice, sequencing will also matter: if a patient with G12C-mutant PDAC receives daraxonrasib as second-line therapy and progresses, olomorasib (or vice versa) could provide a rationally sequenced next option targeting the same pathway with a different mechanism. These are questions for future trials.

Jacob Van Naarden, Lilly’s executive vice-president and oncology president, summarized the clinical rationale: pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses. This Breakthrough Therapy Designation reflects the early potential we are seeing with olomorasib in this setting and the critical need for new treatment options.

---

What Comes Next: The Path to Potential Approval

The Breakthrough Therapy Designation for olomorasib in KRAS G12C-mutant pancreatic cancer triggers intensive FDA guidance on clinical development, which typically means more frequent meetings with the FDA about trial design, endpoint selection, and regulatory strategy. This guidance often accelerates the path from Phase 1/2 data to a pivotal registrational trial and eventual NDA submission.

Based on Lilly’s development program, the likely next steps include:

Mature Phase 1/2 data disclosure: Full results from the pancreatic cancer cohort of LOXO-RAS-20001, including ORR, DOR, PFS, safety profile, and subgroup analyses, are expected at major oncology conferences in late 2026 or 2027.

Pivotal trial design: A registrational Phase 2 or Phase 3 trial in KRAS G12C-mutant advanced PDAC will be required to support NDA submission. Given the small patient population (1 to 2% of PDAC), a randomized Phase 2 or single-arm Phase 2 under accelerated approval may be the pathway, similar to the design used for the first-line approvals of KRAS G12C inhibitors in NSCLC.

Potential NDA submission: Depending on the Phase 1/2 data maturity and pivotal trial readout timing, an NDA submission for pancreatic cancer could potentially occur in 2027 or 2028, though this timeline is speculative.

The lung cancer program is further along: the SUNRAY-01 Phase 3 trial evaluating olomorasib plus pembrolizumab in first-line KRAS G12C-mutant NSCLC with PD-L1 at or above 50% is ongoing, and data from that trial will be the first large-scale Phase 3 test of olomorasib’s clinical benefit. If SUNRAY-01 is positive, it will support an NDA submission for the lung cancer indication while the pancreatic cancer program matures.

HED will continue tracking olomorasib as data emerges, particularly when LOXO-RAS-20001 pancreatic cancer cohort data are fully disclosed and when a pivotal trial design is announced. For related coverage, see our post on daraxonrasib and the RASolute 302 Phase 3 data presented at ASCO 2026, which covers the pan-RAS inhibitor approach and the biology of KRAS-driven pancreatic cancer in depth.

---

Sources

Lilly BTD press release: Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy Designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer. PRNewswire. August 3, 2026.

Lilly investor news: Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy Designation for previously treated KRAS G12C-mutant advanced pancreatic cancer. investor.lilly.com. August 3, 2026.

Targeted Oncology (BTD context, KRAS G12C pancreatic frequency, first-gen agent comparison): FDA Grants Breakthrough Status to Olomorasib in Pancreatic Cancer. targetedonc.com. August 2026.

OncLive (BTD rationale, LOXO-RAS-20001 reference, September 2025 NSCLC BTD context): FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer. onclive.com. August 2026.

CancerNetwork (BTD confirmation, prior NSCLC BTD, daraxonrasib NDA acceptance context): Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer. cancernetwork.com. August 2026.

OncoDaily (mechanism overview, LOXO-RAS-20001 design, van Naarden quote): FDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer. oncodaily.com. August 2026.

Pharmaceutical Business Review (clinical context, Van Naarden quote): FDA designation: Lilly’s olomorasib. pharmaceutical-business-review.com. August 2026.

LOXO-RAS-20001 trial registration: NCT04956640. ClinicalTrials.gov.

SUNRAY-01 trial registration (NSCLC Phase 3): NCT06119581. ClinicalTrials.gov.

Prior September 2025 NSCLC BTD: Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers. investor.lilly.com. September 4, 2025.

HED companion post: Daraxonrasib and the RASolute 302 ASCO 2026 Phase 3 data. healthevidencedigest.com.

ACS pancreatic cancer statistics: Pancreatic Cancer. American Cancer Society.

Disclaimer: Health Evidence Digest provides general information about drug development and regulatory milestones for educational purposes. This content is not a substitute for professional medical advice. Olomorasib is an investigational drug that has not received FDA approval and is not commercially available. Breakthrough Therapy Designation does not constitute FDA approval and does not guarantee that approval will follow. Patients with KRAS G12C-mutant advanced pancreatic cancer should discuss all treatment options, including clinical trial participation, with their treating oncologist. For information on open studies evaluating olomorasib, visit ClinicalTrials.gov and search NCT04956640.

---